Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ADAMTSL3
REST API REST API
Homo sapiens
ADAMTSL3 is differentially expressed in 179 experiments: 139 organism parts: lung, bone marrow, ... (137 more);, 170 disease states: normal, prostate carcinoma, ... (168 more);, 58 cell types 157 cell lines 19 compound treatments and 61 other conditions.
Synonyms KIAA1233, punctin-2
Orthologs ADAMTSL3 (Bos taurus)   F1M767_RAT (Rattus norvegicus)   ADAMTSL3 (Danio rerio)   Adamtsl3 (Mus musculus)   ADAMTSL3 (Gallus gallus)   adamtsl3 (Xenopus laevis)   ADAMTSL3 (Canis familiaris)   (Compare orthologs)
InterPro Term Ig_sub, Immunoglobulin, Peptidase_M12B_ADAM-TS, PLAC, Ig-like, Ig_sub2, Thrombospondin_1_rpt, Ig_I-set
Gene Ontology Term protein binding, metallopeptidase activity, peptidase activity, proteinaceous extracellular matrix, extracellular region, zinc ion binding
UniProt Accession P82987
Search EB-eye ENSG00000156218
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-17189, E-GEOD-6573, E-GEOD-7540, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-14464, E-GEOD-19639, ... (18 experiments)

Factor Value U/D Experiments
LNCaP
2
E-GEOD-14464, E-GEOD-14990
DU145
2
E-GEOD-17482, E-GEOD-20089
HL-60
2
E-MTAB-37, E-GEOD-24147
MCF-7
2
E-GEOD-19639, E-GEOD-20081
Caki2
1
E-MTAB-37
HaCaT
1
E-TABM-420
151 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-3920, E-MEXP-66, E-GEOD-4219, E-GEOD-20677, ... (34 experiments)

Factor Value U/D Experiments
monocyte
2
E-MEXP-2019, E-GEOD-11755
fibroblast
2
E-GEOD-3920, E-GEOD-3204
purified CLL B cells from peripheral blood
1
E-GEOD-22529
skin substitute
1
E-GEOD-3204
secretory cell
1
E-GEOD-3998
cancer cell culture
1
E-GEOD-14990
52 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-22529, E-MEXP-2069, E-MEXP-1121, ... (42 experiments)

Factor Value U/D Experiments
prostate carcinoma
1
3
E-MTAB-62, E-MEXP-1327, E-GEOD-96, E-MTAB-37
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
glioblastoma
2
E-GEOD-4290, E-MTAB-62
lung adenocarcinoma
2
E-GEOD-2514, E-MEXP-231
healthy
1
2
E-GEOD-19188, E-GEOD-22544, E-GEOD-14895
alveolar rhabdomyosarcoma
1
E-MEXP-121
164 more value(s).


Compound treatment

studied in E-GEOD-1615, E-MEXP-1269, E-GEOD-3284, E-GEOD-15205, E-GEOD-5741, ... (11 experiments)

Factor Value U/D Experiments
none
3
E-GEOD-5824, E-GEOD-412, E-GEOD-1615
filtered air
1
E-TABM-127
ethanol
1
E-GEOD-3113
dimethyl sulfoxide
1
E-GEOD-5824
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
TGF
1
1
E-GEOD-15205
13 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MEXP-2359, E-GEOD-4667, E-TABM-145, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578

Genotype
studied in E-GEOD-17476, E-GEOD-21750, E-MEXP-421, E-GEOD-2724, E-GEOD-2725, ... (6 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-TABM-127, E-GEOD-9764, E-MEXP-1273

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, E-TABM-666, ... (22 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561 ... (5 experiments)

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phenotype
studied in E-GEOD-21750

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19246

RNAi
studied in E-GEOD-3697, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-2466

Stimulation
studied in E-GEOD-20114

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Tumor size
studied in E-GEOD-8167

Processing time: 0.505 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM